A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)
Clinical trial NCT04738123 · COMPLETED
Trial details
- NCT number
- NCT04738123
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-06
- Primary completion
- 2022-11-29
- Enrollment
- 256
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.